Fulcrum Therapeutics saw its stock drop about 50% in one day after the FDA raised safety concerns about PRC2-targeting drugs, prompting the company to stop development of its main candidate, pociredir. The company had previously disclosed insider holdings and financial commitments, but the FDA announcement caused a sharp decline from over $20 to around $10 per share. Investors who suffered losses may be eligible for legal action, as investigations focus on whether Fulcrum misled shareholders about its drug program and financial disclosures. No immediate action is required for investors to participate in the investigation, which is handled on a contingency basis without upfront costs.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
